Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8746197 | 1.00 | TSHR (0.67) | TSHRTP53NFKB1CYP2C19FFAR3 | |
| SCHEMBL16807867 | 1.00 | TSHR (0.67) | TSHRTP53NFKB1CYP2C19FFAR3 | |
| SCHEMBL10054702 | 1.00 | TSHR (0.67) | TSHRTP53NFKB1CYP2C19FFAR3 | |
| SCHEMBL16140166 | 1.00 | TSHR (0.67) | TSHRTP53NFKB1CYP2C19FFAR3 | |
| SCHEMBL12654016 | 1.00 | TSHR (0.67) | TSHRTP53NFKB1CYP2C19FFAR3 | |
| Cadaverine Tartrate SCHEMBL3972251 | 0.86 | TSHR (0.77) | TSHRTP53NFKB1CYP2C19FFAR3 | |
| Cadaverine Tartrate SCHEMBL305065 | 0.86 | TSHR (0.77) | TSHRTP53NFKB1CYP2C19FFAR3 | |
| Cadaverine Tartrate SCHEMBL2085067 | 0.86 | TSHR (0.77) | TSHRTP53NFKB1CYP2C19FFAR3 | |
| Cadaverine Tartrate SCHEMBL3972247 | 0.86 | TSHR (0.77) | TSHRTP53NFKB1CYP2C19FFAR3 | |
| Cadaverine Tartrate SCHEMBL28136011 | 0.86 | TSHR (0.77) | TSHRTP53NFKB1CYP2C19FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119198937-A | Organic aerosol source analysis method and system based on-line observation of organic molecular markers | 上海大学 | 2024-12-27 | — | — | CN | claimed |
| CN-119198937-A | Organic aerosol source analysis method and system based on-line observation of organic molecular markers | 上海大学 | 2024-12-27 | — | — | CN | disclosed |
| US-12029735-B2 | Polymorphic compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4252758-A1 | METHOD FOR TREATING PAIN BY VANADIUM COMPOUND | Shenzhen Fangshengtai Medical Technology Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230257337-A1 | METHOD FOR PRODUCING POLYGYLCEROL ESTERS OF POLYCARBOXYLIC ACIDS ESTERIFIED WITH OXOBUTANOL | KETOLIPIX THERAPEUTICS GMBH (DE) | 2023-08-17 | — | — | US | disclosed |
| US-11717549-B2 | Steviol glycoside solubility enhancers | CARGILL, INCORPORATED (US) | 2023-08-08 | — | — | US | disclosed |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010049449-A2 | NOVEL SALTS OF SUNITINIB | LEK PHARMACEUTICALS D.D. (SI) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105794-A1 | PHOTOACTIVABLE NITROGEN BASES | CIBA CORPORATION (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090277356-A1 | Cure Accelerators for Anaerobic Curable Compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281335-A1 | Cure Accelerators for Anaerobic Curable Compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090278084-A1 | Cure accelerators for anaerobic curable compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009104920-A1 | ACID SALT OF TOLTERODINE HAVING EFFECTIVE STABILITY FOR TRANSDERMAL DRUG DELIVERY SYSTEM | SK CHEMICALS CO., LTD. (KR) | 2009-08-27 | — | — | WO | disclosed |
| US-7501439-B2 | Tartrate salt of isofagomine and methods of use | AMICUS THERAPEUTICS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| WO-2008141057-A1 | DEUTERATED PIMAVANSERIN 1- (4-FLU0R0BENZYL) -3- (4-ISOBUTOXYBENZYL) -1- ( L-METHYL-PIPERIDIN-4-YL) -UREA | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029735-B2 | Polymorphic compounds and uses thereof | ALDH2, ALDH1A1, ALDH3A1 | TSHR 4640/4885TP53 342/4885NFKB1 1723/4885 |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | TSHR 2184/4885TP53 449/4885NFKB1 4291/4885 |
| US-20090277356-A1 | Cure Accelerators for Anaerobic Curable Compositions | ACLY, ACAD9, CCNY | TSHR 4841/4885TP53 3091/4885NFKB1 1552/4885 |
| US-20090278084-A1 | Cure accelerators for anaerobic curable compositions | EGLN3, INO80, IDH2 | TSHR 4522/4885TP53 2773/4885NFKB1 2527/4885 |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | TSHR 3795/4885TP53 4809/4885NFKB1 3835/4885 |
| US-11717549-B2 | Steviol glycoside solubility enhancers | SI, TAS2R7, TAS2R31 | TSHR 4189/4885TP53 2053/4885NFKB1 3810/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | TSHR 2184/4885TP53 449/4885NFKB1 4291/4885 |
| US-20090281335-A1 | Cure Accelerators for Anaerobic Curable Compositions | CAT, MRM1, ACLY | TSHR 4604/4885TP53 2311/4885NFKB1 2028/4885 |
| US-20230257337-A1 | METHOD FOR PRODUCING POLYGYLCEROL ESTERS OF POLYCARBOXYLIC ACIDS ESTERIFIED WITH OXOBUTANOL | ACACB, HSD17B12, MCCC2 | TSHR 3845/4885TP53 3977/4885NFKB1 1991/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | TSHR 3422/4885TP53 2940/4885NFKB1 1873/4885 |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | TSHR 1089/4885TP53 4716/4885NFKB1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.